ClinicalTrials.gg
Not yet recruitingNCT07110831FLUDOPRESSUpdated Aug 8, 2025

Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria

A Phase 4 interventional study of Fluoxetine and Cognitive-behavioral therapy in Depression and HIV, sponsored by University of Ibadan. Not yet recruiting at 1 site in Nigeria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by University of Ibadan · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
168
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.

Planned enrollment
16th of 42
168 · median 97
Started
2025
with 4 others
Phase 4
9 of 43
3 open now
Registered
40th of 43
by date

Among the 43 studies testing fluoxetine in Depression, this one is the 16th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 in phase 4, and was the 40th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About fluoxetine

Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing fluoxetine in Depression, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out the usefulness and well-being of people when drugs for treating depression (fluoxetine) and HIV (dolutegravir) are used together. It will also learn about how safe it is to take fluoxetine and dolutegravir together by the people living with HIV (PLWH).

The main questions it aims to answer are:

  • Does fluoxetine (antidepressant) make participants taking anti-HIV (dolutegravir) feel better?
  • What medical problems do participants have when taking fluoxetine and dolutegravir together?
  • Does what people inherit from their parents affect the effectiveness and medical problems that participants have when taking fluoxetine and dolutegravir together? Researchers will compare depression treatments, fluoxetine and psychological treatment [cognitive behavioural therapy (CBT)] together to psychological treatment (CBT) alone among adults PLWH on anti-HIV drug (dolutegravir).

Participants on anti-HIV dolutegravir having depression will:

  • Take both fluoxetine (daily) and CBT together or CBT alone for 3 months
  • Visit the clinic once every week in the first month, then once every 2 weeks for checkups and tests including blood tests
  • Keep a diary of their symptoms and other complaints
Read the detailed description

Depression is the most mental health disorder disorder among people living with HIV (PLWH) and is predictive of increased HIV-related morbidity and mortality. Treatment of depression in the setting of HIV is challenging as adding antidepressants in combination with combination antiretroviral therapy (cART) increases the pill burden and the potential for drug interactions. Studies have reported HIV medication complexity in patients comorbid with major depression to affect cART adherence. Optimal depression control among PLWH predicts and improves cART adherence and treatment outcomes.

Expert consensus is that selective serotonin-reuptake inhibitors (SSRIs) should be the first-line treatment for depression among PLWH. However, it is unclear whether SSRI therapy is effective in PLWH in low-middle-income countries (LMICs). There is an underrepresentation of LMICs in clinical studies involving PLWH and major depression despite the higher burden of PLWH and depression in LMICs than the high-income countries (HICs).

Fluoxetine is the preferred SSRI and most used for the treatment of depression in LMICs and is approved by their drug regulatory authorities. Fluoxetine is the most evaluated SSRI among PLWH with major depression but with different response rates among various ethnic groups reported. Furthermore, while fluoxetine was the most common SSRI used among the available clinical studies among PLWH, the studies did not report the clinical outcomes related to HIV care and cART.

Dolutegravir (DTG), an integrase strand transfer inhibitor, is the preferred and recommended first-line antiretroviral agent for adults and adolescents with HIV in LMICs. DTG is highly effective in suppressing HIV in both treatment-naive and experienced PLWHs, in addition to a low adverse effect profile and a high genetic barrier to developing drug resistance.

The cytochrome P450 (CYP) enzyme system metabolises fluoxetine, while the major enzyme that metabolises DTG is UGT1A1, with some contribution from CYP3A4/5. Fluoxetine and its major metabolite, norfluoxetine, may inhibit multiple enzymes involved in DTG metabolism, especially during chronic administration. A minor interaction via a membrane transporter mechanism may also be more pronounced with chronic use through the inhibition of the P-gp-mediated transport of DTG by fluoxetine. Patients on DTG report neuropsychiatric adverse events, and there is a relationship between plasma DTG trough concentration, neuropsychiatric adverse events, and UGT1A1 single nucleotide polymorphisms (SNPs). Thus, increases in DTG trough concentrations resulting from drug interaction are a potentially important concern.

Understanding potential drug interactions when fluoxetine and DGT-based cART are co-administered together will assist in optimising the dosing regimen, reducing adverse effects, and improving treatment outcomes among PLWH with major depression. To be able to recommend DTG and fluoxetine concomitant use, a prospective study involving PLWH with major depression is proposed. This study will address key knowledge gaps in drug interactions between fluoxetine and DTG among PLWH with major depression.

03

Conditions studied

  • Depression
  • HIV

Keywords

  • Depression
  • Depressive Disorder, Major
  • HIV
  • Antidepressive Agents
  • Selective Serotonin Reuptake Inhibitors
  • Fluoxetine
  • Antiretroviral Therapy, Highly Active
  • Dolutegravir
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18 years and above
  • Willing to provide .
  • Confirmed positive [HIV-seropositive by Enzyme Linked Immunosorbent Assay (ELISA) and Western Blot assays]
  • Willingness to receive and or continue anti-HIV therapy (DTG-based cART) \& adhere to follow-up schedule
  • Willing and able to comply with antidepressant medication(fluoxetine) regimen and scheduled follow-up visits
  • Current depressive symptoms [Subjects with depression (HAM-D-17 score ≥ 8)]
  • Adequate renal function (serum creatinine \< 1.5mg/dl)
  • Adequate liver function [ (AST) and alanine transaminase (ALT) ≤1.5 x )

Exclusion criteria

Exclusion Criteria:

  • Current substance use disorder
  • Imminent risk of suicide- Acute suicidal ideation, gestures, or attempts
  • Presence of psychotic symptoms or known diagnosis of a primary psychotic disorder
  • Presence of symptoms of bipolar disorder
  • Currently taking antipsychotic medication
  • Pregnant or willing to get pregnant or lactation
  • Current or chronic medical condition that would likely preclude adherence to protocol or completion of the trial (per investigator judgment)
  • Antidepressants, mood stabilisers or other neuroleptics intake within three months
  • Use of drugs other than cART, especially known enzyme inducers or inhibitors
  • Abnormal (e.g., prolonged )
  • History of intolerance to study drug (fluoxetine)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Fluoxetine Arm

    Participants with a HAM-D score greater than 13 (moderate, moderately severe, and severe depression) will be recruited and allocated to the intervention group. The psychiatrist will commence the participants on fluoxetine (starting with 20mg daily). The psychiatrist will determine the dose of fluoxetine, and the dose may be adjusted during follow-up. Participants will receive Cognitive Behavioural Therapy (CBT) delivered by a Clinical psychologist in addition to fluoxetine as part of the standard routine care.

    Drug: Fluoxetine · Behavioral: Cognitive-behavioral therapy

  • Active comparator
    Cognitive Behavioural Therapy (CBT) Arm

    Participants with HAM-D score between 8 and 13 (mild depression) will be recruited and allocated to the control group. They will receive only Cognitive Behavioural Therapy (CBT) as per standard routine care.

    Behavioral: Cognitive-behavioral therapy

Interventions

  • Participants in the intervention arm will receive oral fluoxetine capsules starting with 20mg daily for 12 weeks. The dose of the fluoxetine may be adjusted during follow-up by titrating the dose against the participants' response..

    Also known as: Prozac, Fluoxetine hydrochloride, Rapiflux, Sarafem, Selfemra, Fluoxetin, Lilly-110140, N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine

  • BehavioralCognitive-behavioral therapy

    Participants with HAM-D score of between 8 and 13 (mild depression) will receive sessions of Cognitive Behavioural Therapy (CBT) as per standard routine care. Participants in the intervention arm will also receive sessions of CBT as per standard routine care.

    Also known as: Psychotherapy, Cognitive Behavioral Therapy, Cognitive Behavioural Therapy, Cognitive Psychotherapy, Cognitive Therapy, CBT

06

What researchers measure

Primary outcomes

  1. Mean change in the Hamilton Depression Rating Scale (HAM-D) scores from baseline to 12 weeks

    The total HAM-D scores provide an indication of depression and, over time, a guide to evaluate response and recovery. The higher the HAM-D scores, the higher the severity of depression. HAM-D is graded as follows None 0-7 Mild 8-16 Moderate 17-23 Severe ≥ 24

    Time frame: Baseline to the end of treatment at 12 weeks

  2. Mean changes in the AUC of dolutegravir

    The effect of chronic administration of fluoxetine on the steady-state pharmacokinetics of dolutegravir and by intrasubject comparison in the participants. This will be assessed with mean changes in the Area under the plasma concentration-time curve (AUC) before and after the administration of fluoxetine.

    Time frame: Week 2 to the end of treatment at 12 weeks

  3. Mean changes in the Cmax of doultegravir

    The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Maximum plasma concentration (Cmax) before and after the administration of fluoxetine.

    Time frame: Week 2 to the end of treatment at 12 weeks

  4. Mean changes in the Cmin of dolutegravir

    Description: The effect of chronic administration of fluoxetine on the steady-state pharmacokinetics of dolutegravir and by intrasubject comparison in the participants. This will be assessed with mean changes in the Minimum plasma concentration(Cmin) before and after the administration of fluoxetine.

    Time frame: Week 2 to the end of treatment at 12 weeks

  5. Mean changes in the AUC of fluoxetine

    The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Area under the plasma concentration-time curve (AUC) before and after the administration of fluoxetine.

    Time frame: Week 2 to the end of treatment at 12 weeks

  6. Mean changes in the Cmax of fluoxetine

    The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Maximum plasma concentration (Cmax) before and after the administration of fluoxetine

    Time frame: Week 2 to the end of treatment at 12 weeks

  7. Mean changes in the Cmin of fluoxetine

    The effect of chronic administration of dolutegravir on the steady-state pharmacokinetics of fluoxetine by intrasubject comparison in the participants. This will be assessed with mean changes in the Minimum plasma concentration (Cmin) before and after the administration of fluoxetine.

    Time frame: Week 2 to the end of treatment at 12 weeks

Secondary outcomes

  1. Proportion of participants reporting grade 3 or 4 Adverse Events as Assessed by the DAIDS AE Grading Table Corrected Version 2.1

    The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected version 2.1 consists of parameters, or Adverse Events (AEs), with severity grading guidance that is used in DAIDS clinical trials for safety data reporting to maintain accuracy and consistency in the evaluation of AEs. The DAIDS AEs is graded as follows: Grade 1 mild event, Grade 2 moderate event, Grade 3 severe event, Grade 4 potentially life-threatening event and Grade 5 death

    Time frame: Baseline to weeks 2, 4, 8, and 12

  2. Proportion of participants with depression remission at week 12

    To determine the proportion of participants with depression remission at week 12 This will be measured as the proportion of subjects with HAM-D score of less than 8 (HAM-D\<8)

    Time frame: Baseline to the end of treatment at 12 weeks

  3. Proportion of participants with a change of greater than or equal to (≥) 50% in the depression score from baseline to weeks 6, 8, and 12

    To determine the proportion of participants with a change of greater than or equal to (≥) 50% in the HAM-D scores from baseline to weeks 6, 8 and 12

    Time frame: Baseline to weeks 6, 8 and 12

  4. Proportion of participants that drop out (study dropouts) during the study

    To determine that proportion of participants that drop out (study dropouts) from baseline till the end of study at week 12.

    Time frame: Baseline to weeks 2, 4, 6, 8, and 12

  5. Proportion of participants with viral suppression (≤ 50 copies/mL)

    To determine the proportion of participants with HIV viral suppression ( viral load ≤ 50 copies/mL) at the end of study at week 12

    Time frame: Baseline to the end of study at week 12

  6. Mean increase in the CD4 count of participants

    To determine the mean changes in the CD4 counts of participants from baseline to the end of study at week 12

    Time frame: Baseline to the end of study at week 12

  7. AUC of fluoxetine and norfluoxetine

    To determine the Area under the plasma concentration-time curve (AUC) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  8. Cmax of fluoxetine and norfluoxetine

    To determine the Maximum plasma concentration (Cmax) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  9. Cmin of fluoxetine and norfluoxetine

    To determine the Area Minimum plasma concentration (Cmin) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  10. Tmax of fluoxetine and norfluoxetine

    To determine the time to maximum observed plasma concentration (Tmax) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  11. Half-life (t1/2) of fluoxetine and norfluoxetine

    To determine the elimination half-life (t1/2) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  12. Apparent Total Body Clearance (CL/F) of fluoxetine and norfluoxetine

    To determine the Apparent Total Body Clearance (CL/F) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  13. Apparent Volume of Distribution (Vd/F) of of fluoxetine and norfluoxetine

    To determine the Apparent Volume of Distribution (Vd/F) of fluoxetine and norfluoxetine using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  14. AUC of dolutegravir

    To determine the Area under the plasma concentration-time curve (AUC) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  15. Cmax of dolutegravir

    To determine the Maximum plasma concentration (Cmax) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  16. Cmin of dolutegravir

    To determine the Minimum plasma concentration (Cmin) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  17. Tmax of dolutegravir

    To determine the Time to maximum observed plasma concentration (Tmax) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  18. Half-Life (t1/2) of dolutegravir

    To determine the elimination Half-Life (t1/2) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  19. Apparent Total Body Clearance (CL/F) of dolutegravir

    To determine the Apparent Total Body Clearance (CL/F) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

  20. Apparent Volume of Distribution (Vd/F) of dolutegravir

    To determine the Apparent Volume of Distribution (Vd/F) of dolutegravir using intensive and sparse pharmacokinetic sampling at steady state.

    Time frame: Weeks 2, 6,10 and 12

07

Study locations

1 site
08

References and documents

Publications

  • Adedeji WA, Ma Q, Raji AM, Cha R, Rasaki OM, Hutson A, Taiwo BO, Charurat ME, Yusuf OB, Fehintola FA, Gureje O, Morse GD. Prevalence of depression among people living with HIV in rural hospitals in South-Western Nigeria-Association with clinico-demographic factors. AIDS Res Ther. 2023 Dec 16;20(1):89. doi: 10.1186/s12981-023-00586-0. PubMed 38104102 ↗
  • Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019 Apr 1;74(4):1035-1043. doi: 10.1093/jac/dky508. PubMed 30561642 ↗
  • Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteux G. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit. 2003 Dec;25(6):738-42. doi: 10.1097/00007691-200312000-00014. PubMed 14639062 ↗
  • Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6. PubMed 23132334 ↗
  • Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv. 1998 Feb;49(2):239-40. doi: 10.1176/ps.49.2.239. PubMed 9575014 ↗
  • Yagura H, Watanabe D, Kushida H, Tomishima K, Togami H, Hirano A, Takahashi M, Hirota K, Ikuma M, Kasai D, Nishida Y, Yoshino M, Yamazaki K, Uehira T, Shirasaka T. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017 Sep 16;17(1):622. doi: 10.1186/s12879-017-2717-x. PubMed 28915895 ↗
  • Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, Hsu R, Fusco J, Quercia R, Aboud M, Curtis L. Psychiatric Symptoms in Patients Receiving Dolutegravir. J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):423-431. doi: 10.1097/QAI.0000000000001269. PubMed 27984559 ↗
  • Eshun-Wilson I, Siegfried N, Akena DH, Stein DJ, Obuku EA, Joska JA. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD008525. doi: 10.1002/14651858.CD008525.pub3. PubMed 29355886 ↗
  • Lofgren SM, Nakasujja N, Boulware DR. Systematic Review of Interventions for Depression for People Living with HIV in Africa. AIDS Behav. 2018 Jan;22(1):1-8. doi: 10.1007/s10461-017-1906-3. PubMed 28900756 ↗
  • Kumar V, Encinosa W. Effects of HIV Medication Complexity and Depression on Adherence to HIV Medication. Patient. 2010 Mar 1;3(1):59-69. doi: 10.2165/11531090-000000000-00000. PubMed 22273276 ↗
  • Egbe CO, Dakum PS, Ekong E, Kohrt BA, Minto JG, Ticao CJ. Depression, suicidality, and alcohol use disorder among people living with HIV/AIDS in Nigeria. BMC Public Health. 2017 Jun 2;17(1):542. doi: 10.1186/s12889-017-4467-5. PubMed 28577548 ↗
  • Obadeji A, O Ogunlesi A, O Adebowale T. Prevalence and Predictors of Depression in People living with HIV/AIDS Attending an Outpatient Clinic in Nigeria. Iran J Psychiatry Behav Sci. 2014 Spring;8(1):26-31. PubMed 24995027 ↗
  • Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, Katabira E, Nachega JB. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav. 2012 Nov;16(8):2101-18. doi: 10.1007/s10461-011-0087-8. PubMed 22116638 ↗
  • Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, Temoshok L. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med. 1992 Sep-Oct;54(5):588-601. doi: 10.1097/00006842-199209000-00006. PubMed 1438661 ↗
  • Arseniou S, Arvaniti A, Samakouri M. HIV infection and depression. Psychiatry Clin Neurosci. 2014 Feb;68(2):96-109. doi: 10.1111/pcn.12097. Epub 2013 Oct 30. PubMed 24552630 ↗
  • Satz P, Myers HF, Maj M, Fawzy F, Forney DL, Bing EG, Richardson MA, Janssen R. Depression, substance use, and sexual orientation as cofactors in HIV-1 infected men: cross-cultural comparisons. NIDA Res Monogr. 1997;172:130-55. No abstract available. PubMed 9154269 ↗

Individual participant data

Plan to share: Yes — De-identified participant data will be shared post-trial as per NIH and the University of Ibadan's policies.

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After the study

Access criteria: Researchers can access individual participant data by submitting a proposal and data sharing agreement to the principal investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Sep 2027, 25 months later.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 25 months is below that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Aug 8, 2025
StartEst.
Aug 14, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Mar 31, 2028
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07110831
Lead sponsor
University of Ibadan
Responsible party
Waheed Adeola Adedeji (Lecturer, University of Ibadan) — Principal investigator
First posted
Aug 8, 2025
Start date
Aug 14, 2025 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Aug 8, 2025

Study contacts

Waheed A Adedeji
Contact
wad_deji@yahoo.com
+2348038433259
Fatai A Fehintola
Contact
fentolamine@yahoo.com
Waheed A Adedeji
principal investigator · College of Medicine, University of Ibadan, Nigeria

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluoxetine

Start the discussion